Siolta Therapeutics is a biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
Siolta Therapeutics has raised $12.0M in total funding. The most recent round was Series C. The last funding was announced in March 2024.
Siolta Therapeutics's investors include Khosla Ventures, Global Brain Corporation, Seventure Partners, Time Ventures, National Institute of Allergy and Infectious Diseases.
Siolta Therapeutics is headquartered in San Carlos, United States.
Siolta Therapeutics is a biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases.
Siolta Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Siolta Therapeutics — Funding & Investors." VCBacked, March 12, 2024, https://www.vcbacked.co/company/siolta-therapeutics. Accessed October 17, 2026.
VCBacked. (2024). Siolta Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/siolta-therapeutics
{{cite web |title=Siolta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/siolta-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated